SNCA and Parkinson disease: We observed some variability in oligomeric CSF alpha‐synuclein but the combination with TREM2 and DA metabolism as well as plasma alpha‐synuclein suggest that with longer drug exposure oligomeric alpha‐synuclein that longitudinally increases in the CSF of PD patients17, 19, 20, 21 may be a reliable measure of Nilotinib effects on changes of PD‐related biomarkers.60, 61